First Asian approval for ophthalmic drug Jetrea, in Malaysia

18 April 2014

Belgian biotech firm ThromboGenics NV (Euronext Brussels: THR) revealed today (April 18) that Jetrea (ocriplasmin) has been approved in Malaysia for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

The approval, the first in Asia, was gained following a priority review that was granted in September 2013. ThromboGenics’ licensing partner Alcon, the ophthalmic unit of Swiss drug major Novartis (NOVN: VX), holds the commercialization rights to Jetrea outside the USA and will be responsible for the launch of the drug in Malaysia, the first market in Asia.

Drug already launched in some European countries and Canada

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK